drugset / Trial / NCT02667886
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to test different doses of X4P-001 given alone and in combination with axitinib in participants diagnosed with advanced renal cell carcinoma. The goals of the study are to determine the safety and tolerability of X4P-001, as well as the potential effect it may have on the body and the cancer tumor.
Timeline
- Start
- 2016-04-27
- Primary completion
- 2022-04-14
- Completion
- 2022-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 5 mg | Oral |
| Subject | Mavorixafor | Small molecule | 200 mg | Oral |
| Subject | Mavorixafor | Small molecule | 400 mg | Oral |
| Subject | Mavorixafor | Small molecule | 600 mg | Oral |